Persistent postoperative pain and sensory changes following lymph node excision in melanoma patients: a topical review

Studies on complications related to chronic nerve injury following sentinel lymph node biopsy (SLNB) and complete lymph node dissection (CLND) for melanoma are sparse. This review summarizes the existing literature on pain and neuropathic complications in melanoma patients undergoing SLNB with or without CLND. The Cochrane Central Register of Controlled Trials and the Embase and PubMed databases were searched. Full-text English language articles published before June 2013 were included. Prospective and retrospective studies assessing persistent (>1 month) sensory nerve injury, postoperative pain, neuropathic pain, and sensory disturbances following SLNB with or without CLND in melanoma patients were eligible. Nine studies (six prospective and three retrospective) including data for 3632 patients met our inclusion criteria. Outcome parameters were too heterogeneous to conduct a quantitative analysis, and few studies systematically evaluated pain and sensory abnormalities. Persistent postoperative pain was reported in 1–14% of patients following SLNB and in 6–34% following CLND and sensory abnormalities in 0.1–32 and 2–82%, respectively. In the one study that assessed the type of pain, neuropathic pain was suggested to explain persistent pain in 31–66% of patients with SLNB and 82–89% of patients with CLND. Sensory-nerve-related complications in melanoma patients seem to be less pronounced following SLNB compared with CLND. Prospective observational studies are necessary to identify predictors of persistent pain, to evaluate the prevalence and impact of pain and sensory abnormalities, and to develop strategies for prevention of long-term complications.

[1]  H. Hoekstra,et al.  Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[3]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 1995. , 2002, European journal of cancer.

[4]  Henrik Kehlet,et al.  Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention. , 2011, The journal of pain : official journal of the American Pain Society.

[5]  S. Hettiaratchy,et al.  Sentinel lymph node biopsy in malignant melanoma: a series of 100 consecutive patients. , 2000, British journal of plastic surgery.

[6]  M. Rowbotham,et al.  How to reduce the incidence of neuropathic pain: Sentinel node biopsy for diagnosis of metastatic malignant melanoma , 2011, PAIN.

[7]  R. Elashoff,et al.  Sentinel Node Biopsy for Early-Stage Melanoma: Accuracy and Morbidity in MSLT-I, an International Multicenter Trial , 2005, Annals of surgery.

[8]  R. Kreienberg,et al.  Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[10]  T. Jensen,et al.  Persistent Pain After Surgery for Cutaneous Melanoma , 2012, The Clinical journal of pain.

[11]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[12]  H. Hoekstra,et al.  Groin dissection in the treatment of lower-extremity melanoma. Short-term and long-term morbidity. , 1992, Archives of surgery.

[13]  C. Balch,et al.  Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection. , 1992, American journal of surgery.

[14]  H. Kehlet,et al.  Preventive analgesia , 2011, Current opinion in anaesthesiology.

[15]  C. Ingvar,et al.  Morbidity following Prophylactic and Therapeutic Lymph Node Dissection for Melanoma - A Comparison , 1984, Tumori.

[16]  H. Gutman,et al.  Sentinel-lymph-node biopsy (SLNB) for melanoma is not complication-free. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  C. Balch,et al.  Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients , 1983, Cancer.

[18]  H. Haenssle,et al.  Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection , 2008, Melanoma research.

[19]  H. Kehlet,et al.  Persistent postsurgical pain: risk factors and prevention , 2006, The Lancet.

[20]  H. Ris,et al.  Morbidity and outcome after sentinel lymph node dissection in patients with early-stage malignant cutaneous melanoma. , 2002, Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera.

[21]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[22]  S. Raja,et al.  Preventing Chronic Pain following Acute Pain: Risk Factors, Preventive Strategies, and their Efficacy. , 2011, European journal of pain supplements.

[23]  H. Kehlet,et al.  Persistent postsurgical pain: the path forward through better design of clinical studies. , 2010, Anesthesiology.

[24]  H. Kehlet,et al.  Persistent pain, sensory disturbances and functional impairment after immediate or delayed axillary lymph node dissection. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[25]  J. H. Shaw,et al.  Complications and local recurrence following lymphadenectomy , 1990, The British journal of surgery.

[26]  S. Leong Sentinel lymph node mapping and selective lymphadenectomy: The standard of care for melanoma , 2004, Current treatment options in oncology.

[27]  M. Haanpää Are neuropathic pain screening tools useful for patients with spinal cord injury? , 2011, PAIN®.

[28]  A. Bleyer,et al.  Cancer in 15- to 29-year-olds by primary site. , 2006, The oncologist.

[29]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[30]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[31]  T. Jensen,et al.  The neuropathic component in persistent postsurgical pain: A systematic literature review , 2013, PAIN®.

[32]  F. Aubin,et al.  Sentinel lymph node biopsy in melanoma: Our 8-year clinical experience in a single French institute (2002–2009) , 2012, BMC Dermatology.

[33]  M. Kessentini,et al.  A Systematic Literature Review , 2016 .

[34]  N. Finnerup,et al.  Persistent pain after lymph node excision in patients with malignant melanoma is neuropathic , 2011, PAIN.

[35]  M. Ross,et al.  Complications Associated With Sentinel Lymph Node Biopsy for Melanoma , 2003, Annals of Surgical Oncology.